Redwood City, California, April 11, 2016 – Autonomic Technologies, Inc. (ATI) today announced the appointment of Niamh Pellegrini to the position of President and Chief Executive Officer and member of its board of directors. In this role, Ms. Pellegrini will lead the company’s efforts to bring innovative therapies to physicians and their patients who suffer from severe and disabling headaches.
Ms. Pellegrini has over twenty-five years of experience in the healthcare industry including a broad range of operational, strategic and commercial leadership positions. Most recently, Ms. Pellegrini held the position of President, North America at Thoratec, a leader in implantable mechanical circulatory support therapies. Previously, Ms. Pellegrini held senior sales, marketing, business development and general management positions across a number of business units of Johnson and Johnson, including Acclarent and LifeScan.
Additionally, the company has announced that Gerhard Burbach, former CEO of Thoratec and currently an independent board member of ATI, has been appointed Chairman of the Board.
"Niamh brings an impressive track record of driving growth in multinational medical device businesses where she has consistently built and maintained leading market positions," said Mr. Burbach. "We are pleased to have such an accomplished executive join ATI at this important point in the company’s development, and we look forward to strong commercial and clinical success under her very capable leadership."
"It is an exciting time to join ATI as we expand our commercial presence in Europe and accelerate our US clinical trial. The published clinical results for the Pulsante® Microstimulator are compelling and demonstrate that we truly can improve the quality of life for many patients by freeing them from the pain of disabling headaches."